Latest News
Lantern Pharma Inc.
- Lantern Pharma at ThinkEquity Conference: AI drug push gains pace
- Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 15
- Lantern Pharma to Present at ThinkEquity Conference, Highlighting AI-Driven Cancer Drug Development
- Lantern Pharma secures Taiwan clearances for Phase II NSCLC study
- Lantern Pharma receives Taiwan approval for LP-300 trial expansion By Investing.com
- Lantern Pharma Closes $4 Million Registered Direct Offering to Advance AI-Driven Oncology Pipeline
- Lantern Pharma raises up to $8M in registered direct offering
- Lantern Pharma Secures $4 Million in Registered Direct Offering to Advance AI-Driven Oncology Pipeline
- Lantern Pharma raises $4M in registered direct offering By Investing.com
- Lantern Pharma hosts webinar on Open‑Medicine AI multi-agentic drug development platform
- Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development - Slideshow (NASDAQ:LTRN) 2026-09-24
Headlines from the last 30 days, linking to the original publishers. See all market news →